A First in Human Phase I trial of a Vaccine Targeting Mutant KRAS and Mesothelin Epitopes in Combination with an anti-PD-1 Antibody in Patients with Previously Treated, Metastatic, KRAS mutant NSCLC - Stand Up To Cancer

Blog

Posted October 14, 2019

A First in Human Phase I trial of a Vaccine Targeting Mutant KRAS and Mesothelin Epitopes in Combination with an anti-PD-1 Antibody in Patients with Previously Treated, Metastatic, KRAS mutant NSCLC

JOIN OUR COMMUNITY

Sign up to receive emails from Stand Up To Cancer.
   Please leave this field empty
Stand Up to Cancer

Thanks for signing up!
You will hear from us soon.

17215
Array
(
    [0] => 8
)
Array
(
    [0] => 8
)
Array
(
    [0] => 8
)